Choosing the right antibody can make or break your in vivo research. This session will discuss the essential principles behind in vivo antibody selection, knowledge that is critical for any researcher working to achieve reproducible, high-quality results. Attendees will learn why in vitro-grade antibodies are not appropriate for in vivo applications, how endotoxin levels and antibody purity influence experimental outcomes, and how three recurring challenges, Fc mismatch between xenogeneic antibodies and host animals, controlling Fc effector function for targeted delivery, and benchmarking against next-generation modalities, shape preclinical readouts. Drawing on real-world data from Fc-engineered anti-PD-L1 and PD-1 checkpoint models, anti-Ly6G neutrophil depletion, and a mouse CD3×CD20 bispecific evaluated in vitro and in vivo, we'll show how reagent design drives success across oncology, immunology, neuroscience, and in vivo pharmacology. By the end of the session, you'll have the knowledge to make smarter reagent decisions and design your in vivo experiments better. 

May 29th, 2026
7:30 AM | India (GMT +5:30)
10:00 AM  | China (GMT +8)
11:00 AM | Japan (GMT +9)
12:00 PM | Australian (GMT +10)

Speaker:
Kaitlyn Bushey, MBA
Director, Development & Strategic Alliances